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Objective. Ovarian and endometrial cancers coincide rather frequently in the same patient. Few data are available on the
involvement of the speciﬁc morphological subtypes. To identify histological pathways in the synchronous occurrence, a
population-basedstudywasperformedinTheNetherlands.Methods.Usingthenationalpathologydatabase(PALGA)information
of ovarian cancers and of earlier or later cancer in the endometrium was obtained. 5366 Patients were identiﬁed with primary
malignant epithelial or borderline malignancy. Results. In 157 cases (2.9%) a new primary malignancy in the endometrium was
diagnosed (146 within 1 year). The ratio of observed versus expected number of synchronous malignancy in the endometrium
was estimated at 3.6 (95% CI: 2.7–4.7). Among 460 ovarian endometrioid carcinoma patients 53 cases showed a second primary
endometrial cancer; 40 out of these 53 cases (75.5%) showed at both organ sites an endometrioid adenocarcinoma. Conclusion.
These ﬁndings suggest an important role for the endometrioid subtype and prompt to mechanism-based studies incorporating
molecular techniques.
1.Introduction
Approximately 10% of all patients with ovarian cancer
appear to have endometrial cancer synchronously, and 5%
the other way around [1]. However, it is often unclear
whetherthisconferstoprimarytumorsortometastasisfrom
the ovary to the endometrial tumor or vice versa [2, 3].
As described by Herrinton et al., both of these tumors are
probably mechanistically linked to reproductive hormones.
But it is also possible that the joint presence of these two
tumors in diﬀerent organ sites indicates to etiologically
distinct and until now unknown conditions [4].
According to the sparse literature, and which mainly
consists of case series, the simultaneous presence of primary
cancers in the ovary and the endometrium is not well
documented. A strong association has ﬁrst been quantiﬁed
by Sheu et al. [5]. More recently, Van Niekerk et al. [6]
calculated for ovary cancer the observed versus expected
numbers of cancer in the endometrium to be a ratio of 62.3.
This strong relationship prompted us to further evaluate the
risk by histological subtype of the epithelial ovarian tumors.
Most ovarian tumors are adenocarcinomas of diﬀerent
histological subtypes, derived from the surface epithelium
of the ovary [7]. They manifest in various morphological
forms as (cyst)adenocarcinomas with serous, mucinous,
clearcell, or endometrioid diﬀerentiations. Further to that it
is known that primary endometrial neoplasms include the
same subtypes [8].
2.MaterialandMethods
2.1. Design and Patients. We examined the association of
the various histopathological subtypes of ovarian epithelial
cancer in relation to second primary endometrial cancers
using two random samples of the nationwide pathology
database “PALGA” in The Netherlands. Every record in the2 Obstetrics and Gynecology International
PALGA database contains a summary of the full pathology
report and diagnostic codes similar to the Systematized
Nomenclature of Medicine (SNOMED) classiﬁcation of the
College of American Pathologists. From the ﬁrst sample
of the years 1987–1993 we investigated 4577 patients and
from a second sample of the years 1996–2003, a number
of 789 cases [6]. Of these 5366 patients with a new
malignant or borderline malignant epithelial ovarian cancer
diagnosis we also obtained all the other histopathologically
conﬁrmed diagnoses of primary invasive malignancies in the
endometrium if present, and earlier than, concurrently or
after the ovarian tumor was diagnosed.
The scientiﬁc committee of PALGA approved the study
protocol beforehand.
2.2. Measurements. Erroneous coding of the pathologist can
hamper the interpretation of diagnostic codes. Therefore,
we also studied a second more recent and smaller PALGA
dataset. The diagnostic codes in the PALGA database were
reviewed,andthecorrespondingpathologyconclusions,that
is, PALGA codes and PALGA conclusions, as well. Two
experienced pathologists (GPV, JB) reviewed all reports.
The criteria of Young and Scully [8]w e r eu s e df o r
interpretation of synchronous primary tumors of both
organs or of metastasis from one organ to the other. The
diagnosis of independent primary tumors could be made in
most cases. Histological dissimilarity of the tumors at both
organ sites makes two independent synchronous tumors
highly probable. In addition, if the codes and conclusions
report no or only superﬁcial myometrial invasion of the
endometrial tumor and/or both tumors were conﬁned to the
ovary and uterus, the diagnosis of two independent primary
tumors could be reliably made.
If it was doubtful whether or not we were dealing with a
metastasis or recurrence of the primary malignant tumor of
the ovary or a new secondary type of tumor, these uncertain
diagnosis and diﬃcult cases were excluded.
2.3. Data Analysis. Descriptive analysis was applied to the
ovarian epithelial cancers for histopathological subtypes.
For the major histological subtypes the number of patients
observed with a second primary endometrial cancer was
contrasted to the expected number. Expected numbers were
calculated from the 5-year age speciﬁc rates of 2nd primaries
inthetotalovarycancergroup.Theobservedversusexpected
ratio and its 95% conﬁdence interval (CI) were calculated
according to the method of Byar [9].
3. Results
157 (2.9%) cases of the reviewed 5366 patients with ovarian
epithelial cancer appeared to have a second primary malig-
nant tumor in the endometrium (146 within 1 year). In both
samples this percentage was identical (2.9%). The mean age
atdiagnosisofallpatientswithovariancancerwas59.6years;
the 157 cases aged 58.6 years on average. The histological
subtypes and age results are shown in Table 1. In general,
three quarters of all patients aged 50 years and over, except
5366 ovarian carcinoma all subtypes
Ovary endometrioid
subtype 460 (8.6%)
2nd primary malignancy
in the endometrium
157 out of 5366 (2.9%)
Endometrial cancer
53 out of 460 (11.5%)
Endometrial cancer
endometrioid subtype
40 out of 53 (75.5%)
Figure 1: Number of second primary tumors in the endometrium
in 460 patients with endometrioid ovary cancer.
for patients with a mucinous tumor, of whom almost half of
them are under the age of 50.
If a second primary cancer is present in the
endometrium, the endometrioid carcinoma subtype in
the ovary is found to be more frequent in the younger
age-group (<50), while mucinous and serous cancer are less
frequent.
As can be derived from Figure 1, the relative frequency of
endometrioid carcinoma is 8.6%, and also highly prevalent
if a second primary is present in the endometrium (n = 53,
11.5%). We observed that 40 out of these 53 cases (75.5 %)
had an endometrioid adenocarcinoma in the ovary as well as
in the endometrium.
In Table 2, the observed versus expected numbers of
cancer of speciﬁc histology are presented among the 157
cases, having both ovary cancer and a second primary
cancer of the endometrium. For the 53 (33.8%) cases
with endometrioid cancer in the ovary the observed versus
expected ratio was calculated to be 3.6 (95% CI: 2.7–4.7),
implicating a more than threefold risk of second primary in
the endometrium. The other histological subtypes did not
reveal such an excess risk, but a lower ﬁnding (mucinous and
serous carcinoma).
4. Discussion
The present study with data from the PALGA nation-wide
pathology archives in The Netherlands reports a strong
association between the occurrence of epithelial malignancy
in the ovary of the endometrioid histological subtype and a
second primary malignancy in the endometrium. The study
period was comparable with the study of Vernooij et al.,
also from The Netherlands [10]. The latter nationwide study
focused on survival of patients with ovarian cancer and
hospital type. The percentages for the diﬀerent histological
subtypes of ovarian carcinomas (Table 1)a r ev e r ym u c hObstetrics and Gynecology International 3
Table 1
(a) All epithelial ovarian cancers according to histological type and age at diagnosis.
Histological type of ovarian cancers Patients
n
% Range Median Mean % <50 years % ≥ 50 years
Adenocarcinoma 1456 27.1 18–97 64 62.5 16.3 83.7
Clearcell carcinoma 236 4.4 28–88 58 59.2 23.7 76.3
Endometrioid carcinoma 460 8.6 20–86 59 58.8 25.4 74.6
Mucinous carcinoma∗ 733 13.7 14–92 52 52.1 44.9 55.1
Serous carcinoma∗ 1801 33.6 16–100 62 59.9 22.9 77.1
Others∗a 680 12.7 16–100 62 61.5 20.9 81.2
Total 5366 100 14–100 61 59.6 24.2 75.8
(b) Subset of epithelial ovarian cancers with malignancy in the endometrium.
Histological type of ovarian cancers Patients
n
% Range Median Mean % <50 years % ≥ 50 years
Adenocarcinoma 49 31.2 34–85 59 59.8 22.5 87.5
Clearcell carcinoma 3 1.9 53–78 71 67.3 0.0 100.0
Endometrioid carcinoma 53 33.8 36–80 53 54.9 32.1 67.9
Mucinous carcinoma 7 4.5 49–73 57 59.7 14.3 85.7
Serous carcinoma∗ 27 17.2 31–78 68 64.1 11.1 88.9
Othersa 18 11.5 46–78 55 57.9 22.2 79.8
Total 157 100 31–85 57 58.6 22.9 77.1
∗borderline malignancies included.
aincluding mixed carcinomas, anaplastic carcinoma, malignant Brenner tumor, carcinosarcoma, adenosquamous carcinoma, squameus cell carcinoma etc.
Table 2: Association among 157 cases between subtype of epithelial ovarian cancer and second endometrial cancer.
Histology of ovarian tumors Observed Expected O/E
∗∗ 95%-CI
Adenocarcinoma 49 42.82 1.14 (0.85–1.51)
Clearcell carcinoma 3 7.57 0.40 (0.08–1.16)
Endometrioid carcinoma 53 14.93 3.55 (2.66–4.64)
Mucinous carcinoma∗ 7 19.30 0.36 (0.15–0.75)
Serous carcinoma∗ 27 52.62 0.51 (0.34–0.75)
Others 18 19.75 0.91 (0.54–1.44)
∗including borderline malignancies.
∗∗Observed versus Expected number of cases of synchronous endometrial cancer.
concordant across both study groups [10]. Only a slight dif-
ference in the “other” and “adenocarcinoma” categories was
noticed. Precise percentages about the histological subtypes
of ovarian carcinomas are hardly found in the international
literature and gynaecopathological leading handbooks. The
reason is that most referred studies are often small, have
incomplete data, and are diﬃcult to compare. Moreover, if
histological subtypes are given, the percentages in literature
andoverviewsmostlyalsoincludebenignovarianneoplasm’s
[11].
We found in both databases, 1987–1993 and 1996–2003,
a similar 2.9% incidence of synchronous primary ovarian
and endometrial cancer. This is in accordance with the
study of Chiang et al. [1] and Williams et al. [12]. The
objectiveoftheirstudywastoclarifythepotentialfactorsthat
inﬂuence the survival of patients with simultaneous primary
malignancies in the endometrium and ovary. The group
of Chiang [1] retrospectively reviewed the medical records
and pathologic reports from the National Taiwan University
Hospital Cancer Registry from the period 1997–2005. They
detected 27 cases out of 1004 (2.7%) ovarian carcinoma
patients with a malignancy of the endometrium as well.
Williams et al., [12] identiﬁed 1.355 synchronous ovarian
and endometrial cancer cases in a total of 56.986 primary
ovarian cases (2.4%) diagnosed in the period 1973–2005.
They used the SEER deﬁnition of synchronous cancers, that
is, cancer of the endometrium (C54.1) and ovary (C56.9).
Women were excluded from analysis if they were diagnosed
with other primary cancers (e.g., from breast, colon, or
cervix).
Recently, the simultaneous presence of primary cancers
in the ovary and the endometrium has been quantiﬁed4 Obstetrics and Gynecology International
by Soliman et al. [2], and by Hemminki et al. [7, 13].
They also speciﬁed the relation to the histological subtype
of the ovarian tumor. The median age in our study and
in Soliman’s study was almost similar at 53 and 50 year,
respectively, for the endometrioid carcinomas. In our study
53 (33.8%) out of 157 patients having a second malignancy
in the endometrium had an endometrioid malignancy in the
ovary, while 40 (75.5%) out of those 53 cases also showed
an endometrioid subtype in the endometrium. The study of
Soliman reported 57 (68%) individuals with endometrioid
malignancy in the ovary and endometrium out of 84 cases
having indepent primary cancers in both of these organs.
It remains unclear, however, from how many patients with
ovarian malignancy these 84 women originated.
Hemminki et al. [7] reported an age-standardized
incidence ratio of SIR = 86.7, (95% CI: 46.0–148.6) for
ovarian endometrioid cancers and simultaneous primary
endometrialcarcinoma(13cases).Thediﬀerenceinoutcome
with our investigation may be due to the character of their
database, the Swedish Family Cancer-Database, which diﬀers
from our national pathology database of all cancers and not
discerning family background.
In a diﬀerent study Hemminki and Granstr¨ om [13]
describe a strong link of familial ovarian and endometrial
cancers, which appears to be speciﬁc for the endometrioid
morphology. They calculated an SIR = 3.40, (95% CI: 1.80–
5.83), implicating a 3.4-fold risk of endometrioid ovarian
cancer among daughters of mothers presenting endometrial
cancer. Unfortunately, our database did not contain family
background information.
Endometrioid adenocarcinoma is the most common
type of endometrial adenocarcinonomas occurring in more
than three-quarter of all cases [14]. Hyperestrogenic status
plays an essential part in the origin of this subtype of
endometrial carcinoma, as most of these patients have com-
plaints of irregular menses, infertility, obesity, and polycystic
ovary disease. As described by Chiang et al., [1] the patho-
genesis of synchronous endometrial and ovarian cancer is
unclear.ThetheoryofasecondaryM¨ ulleriansystemsaysthat
the epithelium of cervix, uterus, fallopian tubes, ovaries, and
peritoneal surface have shared molecular receptors respond-
ing to carcinogenic stimulus leading to the development of
multiple primary malignancies synchronously. They further
describe that the hypothesis provides an explanation for
synchronous malignancies of similar histology. This may not
be the case in synchronous cancers of dissimilar histology,
and there a diﬀerent mechanism underlying this interesting
phenomenon should be operating. Further studies are
needed to disclose the pathogenesis of synchronous ovarian
and endometrial cancer.
Halperin et al. [15] compared 16 cases of simultaneous
independent primaries of endometrium and ovary, present-
ing the same histological subtype, and 12 cases of primary
endometrial cancer demonstrating ovarian metastases. The
only clinical parameter diﬀerentiating signiﬁcantly between
the groups was the prevalence of familial cancer, being
more frequent in the group of metastatic tumors. They
further notiﬁed that the application of immunohistochem-
ical analysis of estrogen and progesterone receptors is of
value in the diﬀerentiation between cases of simultaneous
independent carcinomas of endometrium and ovary versus
cases of endometrial carcinoma with ovarian metastasis.
We believe that immunohistochemical protein analysis will
probably not discriminate for the same primary epithelial
morphological subtypes arising in diﬀerent organs. It is
expected that concomitant tumors with exactly the same
morphology arising in ovary and endometrium, especially
the endometrioid carcinoma, will show the same immuno-
histochemical expression patterns.
Molecular markers emerging as mutation from PTEN
and LOH analysis as described by Ricci et al. [16]m a yb e
more suitable to establish a correct ﬁnal diagnosis in dis-
tinguishing between metastasis from primary synchronous
carcinomas of the endometrioid subtype of the ovary and
endometrium . The potential of these molecular markers has
to be evaluated in larger series, because so far this has been
done in only few patients [16, 17].
In the study of Soliman et al., 7 (7%) out of 102 women
withsynchronousendometrialandovariancancerhadeither
clinical or molecular criteria suggestive for Lynch syndrome
[18]. They believe that genetic evaluation of women with
synchronous ovarian and endometrial cancer who had a
prior history of at least one ﬁrst-degree relative with an
HNPCC-associatedcancermayappropriatelybeidentiﬁedas
women with Lynch syndrome.
In summary, our results indicate that in 2.9% of patients
diagnosed with epithelial ovarian malignancy a second new
primary malignant tumor is occurring in the endometrium,
especially in women diagnosed with an endometrioid histo-
logical subtype (33.8%). This histological tumor subtype is
most prevalent in the age category of 50–54 years (30.2%)
and shows a ratio of observed versus expected number of
cases with a for endometrium malignancy being 3.6 (95%
CI: 2.7–4.7).
Endometrioid adenocarcinoma at both organs sites is
by far out the most prevalent subtype (75.5%). The other
histological subtypes do not reveal such excess risks. These
ﬁndings should stimulate further molecular studies into the
possibly carcinogenic pathways.
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